20.500.12556/DiRROS-19017 Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors Background. When treating patients with advanced non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors and chemotherapy, intercalated schedule with time separation between the two classes of drugs should avoid their mutual antagonism. In a survey of published trials, we focus on relation between eligibility criteria and effectiveness of intercalated treatment. Methods. Published documents were identified using major medical databases, conference proceedings and references of published trials. Median progression-free survival (PFS) was taken as the basic parameter of treatment efficacy. Correlation between characteristics of patients and median PFS was assessed through the Pearson%s correlation coefficient and the coefficient of determination, separately for first-line and second-line setting. Results. The series includes 11 single-arm trials and 18 randomized phase II or phase III trials with a total of 2903 patients. Treatment-naive patients or those in progression after first-line treatment were included in 16 and 13 trials, respectively. In 14 trials, only patients with non-squamous histology were eligible. Proportion of patients with nonsquamous carcinoma (in first-line setting), proportion of never-smokers (both in first- and second-line setting) and proportion of epidermal growth factor receptor (EGFR) mutant patients (both in first- and second-line setting) showed a moderate or strong correlation with median PFS. In six trials of intercalated treatment applied to treatment-naive EGFR%mutant patients, objective response was confirmed in 83.1% of cases and median PFS was 18.6 months. Conclusions. Most suitable candidates for intercalated treatment are treatment-naive patients with EGFR%mutant tumors, as determined from biopsy or liquid biopsy. For these patients, experience with intercalated treatment is most promising and randomized trials with comparison to the best standard treatment are warranted. lung cancer NSCLC intercalated treatment EGFR tyrosine -kinase inhibitors true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-05-31 14:10:18 2024-05-31 14:10:18 2024-06-01 03:35:36 0000-00-00 00:00:00 2017 0 0 str. 241-251, I No. 3 Vol. 51 Sep. 2017 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2017-09-01 616-006 1318-2099 10.1515/raon-2017-0029 2780283 https://www.degruyter.com/view/j/raon.2017.51.issue-3/issue-files/raon.2017.51.issue-3.xml 1 bfe7a774-1f46-11ef-9c9e-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26093 RAZ_Zwitter_Matjaz_2017.pdf RAZ_Zwitter_Matjaz_2017.pdf 1 45794E5FFDE1B313B706C01B3321D381 b388414c5857b5ec1bc75e57ce50ac2f0f51a8a985e24424b15c264286f0edee f629c763-1f46-11ef-9c9e-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=26094 Onkološki inštitut Ljubljana 0 0 0